Auron Therapeutics Announces FDA Clearance to Initiate Clinical Development of AUTX-703 and Completion of Series B Financing
“I’m proud of the work the Auron team has done establishing a strong product profile for AUTX-703, using an innovative approach to cell state biology to tackle some of the deadliest cancers,” said Kate Yen, Ph.D., Founder and Chief Executive Officer of Auron. “With the funding from this raise, we’re ready to advance AUTX-703 into clinical trials for hematological malignancies and evaluate the promising potential of KAT2A/B in treating inflammatory conditions, all in pursuit of our mission to deliver transformative medicines to patients.”
Share:
More News
“Orphan Drug Designation for SOT106 underscores both the urgent need for new treatment options in osteosarcoma and the strength of our ADC platform,” said Radek Spisek, M.D., Ph.D., chief executive officer of SOTIO. “Osteosarcoma is a devastating disease that has seen little therapeutic innovation over the past four decades. Treatment
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two